Darbepoetin Alfa impact on health status in diabetes patients with kidney disease: A randomized trial

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 4, 2011, Pages 845-855

  Lewis, Eldrin F ^a   Pfeffer, Marc A ^a   Feng, Amy ^b   Uno, Hajime ^a   McMurray, John J V ^c   Toto, Robert ^d   Gandra, Shravanthi R ^b   Solomon, Scott D ^a   Moustafa, Moustafa ^e   Macdougall, Iain C ^f   Locatelli, Francesco ^g   Parfrey, Patrick S ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e South Carolina Nephrology and Hypertension   (United States)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g A MANZONI HOSPITAL   (Italy)

^h Health Sciences Centre St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SENESCENCE; SHORT FORM 36; VISUAL ANALOG SCALE;

AGED; ANEMIA; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEALTH STATUS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 79955568764     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06450710     Document Type: Article

References (45)

1. Covic A, Seica A, Gusbeth-Tatomir P, Goldsmith D: Hemoglobin normalization trials in chronic kidney disease: What should we learn about quality of life as an end point? J Nephrol 21: 478-484, 2008
2. Dharmarajan TS, Norkus EP: Mild anemia and the risk of falls in older adults from nursing homes and the community. J Am Med Dir Assoc 5: 395-400, 2004
3. Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, Soroka S, Mujais S: Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 33-38, 2009
4. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504-510, 2002
5. Klang B, Bjorvell H, Clyne N: Quality of life in predialytic uremic patients. Qual Life Res 5: 109-116, 1996
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444, 1993
7. Alexander M, Kewalramani R, Agodoa I, Globe D: Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 23: 2997-3008, 2007
8. Kimel M, Leidy NK, Mannix S, Dixon J: Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 11: 57-75, 2008
9. Metra M, Cannella G, La Canna G, Guaini T, Sandrini M, Gaggiotti M, Movilli E, Dei Cas L: Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. Am J Cardiol 68: 1060-1066, 1991
10. Finkelstein FO, Wuerth D, Finkelstein SH: Health related quality of life and the CKD patient: Challenges for the ne-phrology community. Kidney Int 76: 946-952, 2009
11. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbe-poetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
12. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H: Baseline charac teristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 54: 59-69, 2009
13. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13-19, 1997
14. Cella D, Lai JS, Chang CH, Peterman A, Slavin M: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer Jan 94: 528-538, 2002
15. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24: 547-561, 2002
16. Brazier J, Jones N, Kind P: Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 2: 169-180, 1993
17. Williams A, Buxton M, O'Hanlon M, Rushby J, Pekurinen M, Sintonen H, Bjork S, Lindgren B, Perrson U, Brooks R, Nord E, Allison R, Butler C, Rabin R, Rosser R, Selai C, Bonsel G, Essink-Bot ML, van Hout B, deCharro F, Gudex C, Kind P: EuroQol: A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16: 199-208, 1990
18. Manns BJ, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C: Dialysis adequacy and health related quality of life in hemodialysis patients. Asaio J 48: 565-569, 2002
19. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L: Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 305: 160-164, 1992
20. ® Health Survey (Standard and Acute Forms), Lincoln, RI, Quality Metrics Incorporated, 2002
21. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML: Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. Am J Kidney Dis 55: 519-534, 2009
22. Hays RD, Woolley JM: The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 18: 419-423, 2000
23. Berry C, McMurray J: A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 16: 247-271, 1999
24. Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, TenVergert EM, van Tinteren H, Willemse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG: Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol 25: 5403-5409, 2007
25. Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA: Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myo-cardial Infarction Trial (VALIANT). Am Heart J 150: 323-329, 2005
26. Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, Powe NR: Changes in quality of life during hemodialysis and peritoneal dialysis treatment: Generic and disease specific measures. J Am Soc Nephrol 15: 743-753, 2004
27. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M: The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20: 1501-1510, 2004
28. Teehan BP, Krantz S, Stone WA, Graber SE, Abraham P, Dauer A, Eschbach J, Adamson J, Friedman E, Brown CD, Greenwald J, Lim V, McMahon FG, Orringer E, Mattern WD, Raja R, Rud-nick M, Cohen RM, Schwartz AB, Shadur C, Sheth A, Chew R, Sullivan D, Thompson D, Abels R: Double-blind,placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients.The US Recombinant Human Erythropoi-etin Predialysis Study Group.Am J Kidney Dis 18: 50-59, 1991
29. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI: The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis 14: 486-495, 1989
30. Benz R, Schmidt R, Kelly K, Wolfson M: Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2: 215-221, 2007
31. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for pre-dialysis chronic renal disease patients. Am J Kidney Dis 25: 548-554, 1995
32. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
33. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005
34. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J: The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther 25: 1786-1805, 2003
35. Kallich J, McDermott A, Xu X, Fayers P, Cella D: The relationship between patient knowledge of hemoglobin levels and health-related quality of life. Qual Life Res 15: 57-68, 2006
36. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ: The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-analysis. Arch Intern Med 169: 1104-1112, 2009
37. Kusek JW, Greene P, Wang SR, Beck G, West D, Jamerson K, Agodoa LY, Faulkner M, Level B: Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency: The African American Study of Kidney Disease and Hypertension Trial. Am J Kidney Dis 39: 513-524, 2002
38. Wight JP, Edwards L, Brazier J, Walters S, Payne JN, Brown CB: The SF36 as an outcome measure of services for end stage renal failure. Qual Health Care 7: 209-221, 1998
39. Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA: Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 9: 83-91, 2007
40. Hicks LS, Cleary PD, Epstein AM, Ayanian JZ: Differences in health-related quality of life and treatment preferences among black and white patients with end-stage renal disease. Qual Life Res 13: 1129-1137, 2004
41. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW: Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 25: 458-463, 2002
42. Hjollund NH, Andersen JH, Bech P. Assessment of fatigue in chronic disease: A bibliographic study of fatigue measurement scales. Health Qual Life Outcomes 5: 12-16, 2007
43. Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P: The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 24: 1091-1100, 2008
44. Martin ML PD, Gandra SR, Bennett AV, Leidy NK, Nissenson AR, Finkelstein FO, Lewis EF, Wu AW, Ware JE: Content Validity of SF-36 Energy and Physical Function scales in patients with type 2 diabetes and non-dialysis chronic kidney disease related anemia (abstract). 2009 International Society for Quality of Life Research meeting abstracts. QLR J 18 (Supplement) 1-144, Abstract 1699, 2009
45. Tong EM, Nissenson AR: Erythropoietin and anemia. Semin Nephrol 21: 190-203, 2001